If drugs are not taken - How different antipsychotics influence compliance of schizophrenic patients;Wenn arzneimittel nicht eingenommen werden - Der einfluss verschiedener antipsychotika auf das complianceverhalten schizophrener patienten

Fortschritte der Neurologie Psychiatrie

Volumn 75, Issue 8, 2007, Pages 473-477

  Schorr, S G ^a   Brouwers, J R B J ^a   Taxis, Katja ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Antipsychotic drugs; Compliance; Drug safety; Drug therapy; Schizophrenia

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

DRUG EFFECT; DRUG USE; HUMAN; LONG TERM CARE; MEDICAL LITERATURE; PATIENT COMPLIANCE; PATIENT MONITORING; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW;

ANIMALS; ANTIPSYCHOTIC AGENTS; HUMANS; PATIENT COMPLIANCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 34547917258     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-980067     Document Type: Review

References (27)

1. Cramer J, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998; 49: 196-201
2. Haynes RB. Introduction. In: Haynes RB, Taylor DW, and Sackett DL (Hrsg). Compliance in health care. Baltimore, Maryland: The John Hopkins University Press, 1979: 1-7
3. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-497
4. Vermeire E, Hearnshaw H, Royen P Van, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 2001; 26: 331-342
5. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication: nonadherence in patients with schizophrenia. J Clin Psychiatry 2002; 63: 892-909
6. Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001; 179: 290-299
7. Swartz MS, Swanson JW, Wagner HR, Burns BJ, Hiday VA. Effects of involuntary outpatient commitment and depot antipsychotics on treatment adherence in persons with severe mental illness. J Nerv ment Dis 2001; 189: 583-592
8. Davis JM, Metalon L, Watanabe MD, Blake L. Depot antipsychotic drugs. Place in therapy. Drugs 1994; 47: 741-773
9. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997; 23: 637-651
10. Otte C, Naber D. Compliance in der Therapie mit Neuroleptika, Antidepressiva und Lithium. Bundesgesundheitsblatt 2001; 44: 14-19
11. Citrome L, Volavka J. The promise of atypical antipsychotics fewer side effects mean enhanced compliance and improved functioning. Postgraduate Medicine 2004; 116: Issue 4
12. Voruganti L, Cortese L, Owyeumi L, Kotteda V, Cernovsky Z, Zirul S, Awad A. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res 2002; 57: 201-208
13. Valenstein M, Blow FC, Copeland LA, McCarthy JF, Zeber JE, Gillon L, Bingham CR, Stavenger T. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 2004; 30: 255-264
14. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: Is there a difference between typical and atypical agents? Am J Psychiatry 2002; 159: 103-108
15. Olfson M, Mechanic D, Hansell S, Boyer CA, Weiden PJ. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000; 51: 216-222
16. Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, Jeste DV. Adherence to treatment with antipsychotic medication and health care costs among medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004; 161: 692-699
17. Diaz E, Neuse E, Sullivan MC, Pearsall HR, Woods SW. Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry 2004; 65: 354-360
18. Rosenheck R, Chang S, Choe Y, Cramer J, Xu W, Thomas J, Henderson W, Charney D. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. J Clin Psychiatry 2000; 61: 382-386
19. Rijcken CAW, Tobi H, Vergouwen ACM, de Jong-van den Berg LTW. Refill rate of antipsychotic drugs: an easy and inexpensive method to monitor patients compliance by using computerised data. Pharmacoepidemiology and Drug Safety 2004; 13: 365-370
20. Menzin J, Boulanger L, Friedman M, Mackell J, LLoyd JR. Treatment adherence associated with conventional and atypical antipsychotics in a large state medicaid program. Psychiatr Serv 2003; 54: 719-723
21. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346: 16-22
22. Grunebaum MF, Weiden PJ, Olfson M. Medication supervision and adherence of persons with psychotic disorders in residential treatment settings: a pilot study. J Clin Psychiatry 2001; 62: 394-399
23. Thieda P, Beard S, Richter A, Kane J. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 2003; 54: 508-516
24. Vanelli M, Burstein P, Cramer J. Refill patterns of atypical and conventional antipsychotic medications at a national retail pharmacy chain. Psychiatr Serv 2001; 52: 1248-1250
25. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223
26. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions. JAMA 2002; 288: 2868-2879
27. Kyngas H, Duffy ME, Kroll T. Conceptual analysis of compliance. J Clin Nurs 2000; 9: 5-12